During treatment and follow-up in treatment-free intervals, regular MM disease monitoring is primarily performed by sequential measurements of the M-protein, and if indicated, BM aspiration, e.g. measurement of minimal residual disease (MRD) and/or imaging investigations [10].Very recently, a new wave of immunotherapies including chimeric antigen receptor (CAR) T-cells and bispecific antibodies have shown unprecedented therapeutic efficacy in patients with relapsed and refractory MM, which will transform the treatment landscape and further improve the prognosis of MM patients [11, 12]. The gene discussed is MYOM2; the disease is Miyoshi myopathy.